Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc (NY: CYBN )

9.820 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc

< Previous 1 2 3 4 5 6 7 8 9
...
38 39 Next >
Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023
From Cybin Inc.
Via Business Wire
Cybin Reports Access To $101M To Sustain Deuterated Psychedelics Programs, Q2 Numbers & 2024 Goals
Clinical-stage psychedelics biotech Cybin Inc. (NYSE: CYBN) released its financial results for second quarter ended September 30, 2023. 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Poster Presentation at Neuroscience 2023, Closing of Underwritten Offering and Q2 Results, Recent Business Highlights
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting
From Cybin Inc.
Via Business Wire
Cybin Reports Second Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Cybin Announces Closing of Offering of Units Led by One of the Company’s Largest Institutional Shareholders
From Cybin Inc.
Via Business Wire
Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More
Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans? 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Cybin Launches Five-Day Units Offering For Up To $64M, Suspends Prior LPC Funding Deal
Clinical-stage psychedelics biotech Cybin Inc. (NYSE: CYBN) has announced a new underwritten offering of 66.66 million units to one of its largest institutional shareholders as well as new... 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces up to US$64M Offering
Via Investor Brand Network
Cybin Announces up to US$64 Million Offering of Units
From Cybin Inc.
Via Business Wire
Psyched: DEA's Denial Overruled, Fed Psychedelics Change, Psilocybin For Depression, States Reform & More
DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court 
Via Benzinga
Topics Economy
Exposures Interest Rates
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Announces Participation at Upcoming Milken Institute Future of Health Summit
Via Investor Brand Network
Cybin to Participate at the 2023 Milken Institute Future of Health Summit
From Cybin Inc.
Via Business Wire
Single Dose Of Cybin's Psilocybin Shows Compelling Patient Outcomes, Phase 2 Results Find
Psychedelics company Cybin Inc. (NYSE: CYBN) shared its Phase 2 study interim results for its psilocybin analog CYB003 
Via Benzinga
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Releases Update, Notes Upcoming Pipeline Milestones
Via Investor Brand Network
Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline
From Cybin Inc.
Via Business Wire
Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose
From Cybin Inc.
Via Business Wire
Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More
Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Cybin's Deuterated Psychedelics Programs Protected By Three New International Patents
Cybin’s (NYSE: CYBN) deuterated psychedelics programs received two patent grants from the United States Patent and Trademark Office (USPTO,) and one from the European Patent Office (EP.) 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Expands Portfolio to Secure New European Patent
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Granted Two US Patents Protecting Exclusive Deuterated DMT Program
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT Program
From Cybin Inc.
Via Business Wire
Cybin Officially Owns Small Pharma: Plans For New 'International Leader' In Psychedelic Therapeutics
Psychedelics companies Cybin Inc. (NYSE: CYBN) and Small Pharma Inc. (OTCQB: DMTTF) have completed their August acquisition agreement. 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Strategic Acquisition, Poised as Leader in Psychedelics Sector
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics
From Cybin Inc.
Via Business Wire
Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted
Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts 
Via Benzinga
Small Pharma's Q2 2024 Financial Highlights Ahead Of Cybin Merger For Global DMT Business
Small Pharma Inc. (OTCQB: DMTTF), the short-acting psychedelics biotech about to be purchased by Cybin Inc. 
Via Benzinga
Moving Closer To Cybin Acquisition, Small Pharma Obtains Final Order Approving Arrangement
Short-acting psychedelics biotech Small Pharma Inc. 
Via Benzinga
Small Pharma Obtains Final Order Approving Arrangement
From Cybin Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
38 39 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.